Molecular Glues Market By Type (Monovalent Molecular Glues, Bivalent Molecular Glues); By Application (Oncology, Neurology, Immunology, Others); By End-User (Pharmaceutical Companies, Research Institutes, Biotechnology Companies); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

The molecular glues market was USD 2.1 billion in 2023 and is expected to be worth USD 5.6 billion by 2030, with a CAGR of 14.8%. This growth can be attributed to the development in proteomics, higher spending on precision medicine, and the rise in interest in targeted protein degradation (TPD) technologies.

 

The Molecular Glues Market is primarily concerned with small molecules that bind and fix specific protein-protein interfaces or promote the degradation of a target protein by manipulating cellular signaling pathways. These molecules are transforming drug discovery in oncology, immunology, and neurodegeneration by targeting previously undruggable proteins. Molecular glues uniquely bind two normally non-interacting proteins, offering a novel therapeutic approach.

 

Molecular Glues Market: Revolutionizing Targeted Protein Degradation and Drug Discovery

Molecular Glues Market: Advancements in Protein Degradation Technologies Drive Growth

Advancements in Protein Degradation Technologies: The emerging field of proteomics and progression in the arena of protein degradation, PROTACs (Proteolysis-Targeting Chimeras), and molecular glues are key factors. The use of molecular glues is increasingly being accepted for the advancement beyond the small molecule inhibitors. More than $ 6 billion was spent worldwide in 2022 on R&D of targeted protein degradation, including investments in developing molecular glue.

 

Rising Prevalence of Cancer and Neurodegenerative Diseases: The increasing cases of cancer, in addition to the neurodegenerative diseases the world is facing, has led to the need for new and better treatment methods. Molecular glues are especially relevant in oncology because they can selectively degrade proteins causative of cancer and previously considered druggable. Example: In 2023, a molecular glue that binds selectively to BRD4, a protein associated with worse prognosis tumors, was launched in clinical trials and showed promising first results.

 

Expanding Investment in Precision Medicine: The growth of precision and personalized medicine has brought attention to molecular glues. These molecules allow very specific therapeutic approaches, which may be suitable for targeted treatments. In 2023, a molecular glue therapy producer received $250 million, which was aimed at a range of therapies for genetic disorders.

 

Molecular Glues Market: Unlocking Applications Beyond Oncology

Application Beyond Oncology:  molecular glue has its major application in oncology, but there are increasing attempts to explore its utility across various other disease segments, such as autoimmune and cardiovascular diseases. A study conducted in 2023 pointed towards the possibility of using molecular glues to target inflammatory disorders based on the alteration of immune cell signaling.

 

Emerging Markets and Research Hubs: Asia-Pacific and Latin American emerging economies are also developing strong drug discovery platforms, which present untapped opportunities in molecular glue science and product development. The Asia-Pacific region is expected to grow at a CAGR of 16.2% due to favourable government support and rising investment in biotech research and development.

 

Molecular Glues Market: High R&D Costs and Long Development Timelines Pose Challenges

High R&D Costs and Long Development Timelines: The use of molecular glues is capital or time-intensive due to the cost of proteomics, structural biology, and clinical trials, among other things. Molecular glue therapy can take, on average, 10-15 years and up to $2 billion to develop and get approved.

 

Complexity of Protein Degradation Pathways: Many promising approaches in the field of protein degradation have been confined to a few initial phases due to the complexity of the processes under investigation. A molecular glue research study in 2023 revealed that there is limited understanding of the ubiquitin-proteasome system, which is a pathway targeted by molecular glues.

 

Molecular Glues Market Segmentation

By Type

• Monovalent Molecular Glues

• Bivalent Molecular Glues

 

By Application

• Oncology

• Neurology

• Immunology

• Others

 

By End-User

• Pharmaceutical Companies

• Research Institutes

• Biotechnology Companies

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Molecular Glues Market: Asia-Pacific Set to Grow at 16.2% CAGR with Expanding Biotech Hubs

The largest revenue share of the molecular glues market is held by North America, which contributed to 45% of the global revenue in 2023 because of increased investment in the biotechnology domain, great development of drug discovery processes, and effective partnerships between universities and industrial organizations. The U.S. generated more than 80% of the North American market revenue; over $3 billion would be dedicated to protein degradation research in 2023. The molecular glue therapy designed to target a critical oncogenic protein received fast-track designation from the FDA in 2023, which reflects the leadership of the region in terms of regulation and clinical developments.

 

Europe ranks second in the adoption of biomarkers in drug development due to high research, development, and governmental support for precision medicine and successful partnerships of universities and academic institutions with biotech companies. Example: The United Kingdom and Germany are primary contributors to molecular glue technology research because of their interest in treating neurodegenerative diseases.

However, the Asia-Pacific is still the most rapidly growing B2B E-Commerce market, with an expected CAGR of 16.2% during the forecast period. Key drivers include escalating healthcare costs, enhanced drug development, and higher enrolment in worldwide trials. China and Japan are two significant markets, and several biotech startups are already developing molecular glues for oncology and rare diseases.

 

Molecular Glues Market: Industry Leaders Driving Innovation and Collaboration

• C4 Therapeutics

• Arvinas Inc.

• Kymera Therapeutics

• Nurix Therapeutics

• Celgene Corporation (a Bristol-Myers Squibb company)

• Amgen Inc.

• Novartis AG

• Genentech (a Roche subsidiary)

• Pfizer Inc.

• Merck & Co., Inc

 

Future Outlook

The molecular glues market is expected to grow rapidly due to progress on the proteomics front, increasing focus on precision medicine, and growing use across disease classes. Subsequent advances are anticipated to include individualised treatments, organoid application in drug discovery with the help of artificial intelligence, and novel molecular glues with increased stability and selectivity.

 

Molecular glues will likely become even more prevalent by the year 2030 in both oncology and non-oncology contexts, as academia and industry work in conjunction to move forward. New entrants with innovative and affordable service propositions are likely to have a huge impact on the potential configuration of the global market.

 

Therefore, the molecular glues market is several folds an evolving, vibrant and innovation-oriented industry with huge market opportunity in revolutionizing drug discovery and therapeutic management. Those stakeholders that invest in R&D, regional expansion, and strategic partners will benefit enormously from this innovative field.